Seeking Alpha

Galena Biopharma GALE +5.4%) moves up after releasing positive data from its phase 1/2 clinical...

Galena Biopharma GALE +5.4%) moves up after releasing positive data from its phase 1/2 clinical trial of tumor drug NeuVax. According to the trial, the drug showed a consistent reduction of circulating tumor cells in vaccinated patients. Final results will be reported at the San Antonio Breast Cancer Symposia in December 2012.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs